Tags

Type your tag names separated by a space and hit enter

Antidepressant activity of curcumin: involvement of serotonin and dopamine system.
Psychopharmacology (Berl). 2008 Dec; 201(3):435-42.P

Abstract

RATIONALE

Curcumin is a major active principle of Curcuma longa, one of the widely used preparations in the Indian system of medicine. It is known for its diverse biological actions.

OBJECTIVE

The present study was designed to investigate the involvement of monoaminergic system(s) in the antidepressant activity of curcumin and the effect of piperine, a bioavailability enhancer, on the bioavailability and biological effects of curcumin.

METHODS AND OBSERVATIONS

Behavioral (forced swim test), biochemical (monoamine oxidase (MAO) enzyme inhibitory activity), and neurochemical (neurotransmitter levels estimation) tests were carried out. Curcumin (10-80 mg/kg, i.p.) dose dependently inhibited the immobility period, increased serotonin (5-hydroxytryptamine, 5-HT) as well as dopamine levels (at higher doses), and inhibited the monoamine oxidase enzymes (both MAO-A and MAO-B, higher doses) in mice. Curcumin (20 mg/kg, i.p.) enhanced the anti-immobility effect of subthreshold doses of various antidepressant drugs like fluoxetine, venlafaxine, or bupropion. However, no significant change in the anti-immobility effect of imipramine and desipramine was observed. Furthermore, combination of subthreshold dose of curcumin and various antidepressant drugs resulted in synergistic increase in serotonin (5-HT) levels as compared to their effect per se. There was no change in the norepinephrine levels. The coadministration of piperine (2.5 mg/kg, i.p.), a bioavailability enhancing agent, with curcumin (20 and 40 mg/kg, i.p.) resulted in potentiation of pharmacological, biochemical, and neurochemical activities.

CONCLUSION

The study provides evidences for mechanism-based antidepressant actions of curcumin. The coadministration of curcumin along with piperine may prove to be a useful and potent natural antidepressant approach in the management of depression.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kulkarni SK
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. skpu@yahoo.com
Bhutani MK
No affiliation info available
Bishnoi M
No affiliation info available

MeSH

AlkaloidsAnimalsAntidepressive AgentsBehavior, AnimalBenzodioxolesBiogenic MonoaminesBiological AvailabilityCurcuminDopamineDose-Response Relationship, DrugDrug SynergismDrug Therapy, CombinationImmobility Response, TonicInjections, IntraperitonealMaleMiceMice, Inbred StrainsMonoamine OxidaseMonoamine Oxidase InhibitorsPiperidinesPolyunsaturated AlkamidesReserpineSelegilineSerotoninSwimmingTime FactorsTranylcypromine

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18766332

Citation

Kulkarni, Shrinivas K., et al. "Antidepressant Activity of Curcumin: Involvement of Serotonin and Dopamine System." Psychopharmacology, vol. 201, no. 3, 2008, pp. 435-42.
Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl). 2008;201(3):435-42.
Kulkarni, S. K., Bhutani, M. K., & Bishnoi, M. (2008). Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology, 201(3), 435-42. https://doi.org/10.1007/s00213-008-1300-y
Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant Activity of Curcumin: Involvement of Serotonin and Dopamine System. Psychopharmacology (Berl). 2008;201(3):435-42. PubMed PMID: 18766332.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antidepressant activity of curcumin: involvement of serotonin and dopamine system. AU - Kulkarni,Shrinivas K, AU - Bhutani,Mohit Kumar, AU - Bishnoi,Mahendra, Y1 - 2008/09/03/ PY - 2008/08/04/received PY - 2008/08/10/accepted PY - 2008/9/4/pubmed PY - 2009/4/8/medline PY - 2008/9/4/entrez SP - 435 EP - 42 JF - Psychopharmacology JO - Psychopharmacology (Berl) VL - 201 IS - 3 N2 - RATIONALE: Curcumin is a major active principle of Curcuma longa, one of the widely used preparations in the Indian system of medicine. It is known for its diverse biological actions. OBJECTIVE: The present study was designed to investigate the involvement of monoaminergic system(s) in the antidepressant activity of curcumin and the effect of piperine, a bioavailability enhancer, on the bioavailability and biological effects of curcumin. METHODS AND OBSERVATIONS: Behavioral (forced swim test), biochemical (monoamine oxidase (MAO) enzyme inhibitory activity), and neurochemical (neurotransmitter levels estimation) tests were carried out. Curcumin (10-80 mg/kg, i.p.) dose dependently inhibited the immobility period, increased serotonin (5-hydroxytryptamine, 5-HT) as well as dopamine levels (at higher doses), and inhibited the monoamine oxidase enzymes (both MAO-A and MAO-B, higher doses) in mice. Curcumin (20 mg/kg, i.p.) enhanced the anti-immobility effect of subthreshold doses of various antidepressant drugs like fluoxetine, venlafaxine, or bupropion. However, no significant change in the anti-immobility effect of imipramine and desipramine was observed. Furthermore, combination of subthreshold dose of curcumin and various antidepressant drugs resulted in synergistic increase in serotonin (5-HT) levels as compared to their effect per se. There was no change in the norepinephrine levels. The coadministration of piperine (2.5 mg/kg, i.p.), a bioavailability enhancing agent, with curcumin (20 and 40 mg/kg, i.p.) resulted in potentiation of pharmacological, biochemical, and neurochemical activities. CONCLUSION: The study provides evidences for mechanism-based antidepressant actions of curcumin. The coadministration of curcumin along with piperine may prove to be a useful and potent natural antidepressant approach in the management of depression. SN - 0033-3158 UR - https://www.unboundmedicine.com/medline/citation/18766332/full_citation/Antidepressant_activity_of_curcumin:_involvement_of_serotonin_and_dopamine_system_ L2 - https://dx.doi.org/10.1007/s00213-008-1300-y DB - PRIME DP - Unbound Medicine ER -